CDXS - Codexis, Inc.

Insider Purchase by Opaleye Management Inc. (10%)

1 Year
After Trade
Before Trade

Loading data...

Trade Summary

6 months ago, Opaleye Management Inc., serving as 10% owner at Codexis, Inc. (CDXS), purchased 85,000 shares at $2.68 per share, for a total transaction value of $227,921.00. Following this transaction, Opaleye Management Inc. now holds 12,795,000 shares of CDXS.

This purchase represents a 1.00% increase in Opaleye Management Inc.'s stake in the company. This is considered a medium-conviction trade.

The trade was executed on Thursday, July 31, 2025 and publicly disclosed via SEC Form 4 filing on Monday, August 4, 2025, 4 days after the trade was made.

Codexis, Inc. operates in the HEALTHCARE sector, specifically within the BIOTECHNOLOGY industry. Insider buying activity in this sector can provide valuable signals about industry trends and company-specific developments.

Opaleye Management Inc.

Opaleye Management Inc.

10%

Opaleye Management Inc. is a hedge fund management firm based in Boston, Massachusetts, founded in February 1996 by James Aaron Silverman, who serves as President and Chief Compliance Officer.[[1]](https://www.insidermonkey.com/hedge-fund/opaleye+management/647/) Originally named Risk/Reward Capital Management Corporation, it rebranded to Opaleye Management in 2014 and specializes in investing in small and mid-sized biotechnology and specialty pharmaceutical companies in the US and internationally.[[1]](https://www.insidermonkey.com/hedge-fund/opaleye+management/647/) The firm manages approximately $639 million in discretionary assets for two clients, with recent 13F filings showing a portfolio value of around $494 million, including top holdings like Ocular Therapeutix Inc. and Harrow Inc.[[1]](https://www.insidermonkey.com/hedge-fund/opaleye+management/647/)[[6]](https://whalewisdom.com/filer/opaleye-management-inc) Opaleye Management Inc. is frequently classified as a 10% owner in various portfolio companies due to its significant stakes, such as in Eton Pharmaceuticals Inc., Protara Therapeutics Inc., and recently Sol-Gel Technologies Ltd. (SLGL), where it purchased 66,304 shares to increase its position.[[2]](https://www.gurufocus.com/insider/52142/opaleye-management-inc.)[[10]](https://www.tipranks.com/news/insider-trading/major-stakeholder-makes-bold-new-move-in-sol-gel-technologies-insider-trading) As of late 2025, its estimated net worth from insider holdings exceeds $378 million across multiple biotech firms.[[2]](https://www.gurufocus.com/insider/52142/opaleye-management-inc.) The firm continues active trading, including recent purchases in SANUWAVE Health, Inc.[[3]](https://www.investing.com/news/insider-trading-news/opaleye-management-buys-sanuwaves-health-shares-worth-38360-93CH-4280776)

View full insider profile →

Trade Price

$2.68

Quantity

85,000

Total Value

$227,921.00

Shares Owned

12,795,000

Trade Date

Thursday, July 31, 2025

206 days ago

SEC Filing Date

Monday, August 4, 2025

Filed 4 days after trade

HEALTHCAREBIOTECHNOLOGY

About Codexis, Inc.

Company Overview

No company information available
View news mentioning CDXS

💬 Want Deeper Insight?

Use our AI assistant to ask questions about this trade, the insider, or the company.

Chat with AI

Share this trade

https://insidersignal.ai/trade/104020

🚀 Track Insider Trades in Real-Time

Create a free account to access our full database of insider trades, AI-powered analysis, price alerts, and discover what corporate executives are buying and selling.

✓ Free forever plan available  •  ✓ No credit card required  •  ✓ Cancel anytime